Last reviewed · How we verify
EVER4010001
At a glance
| Generic name | EVER4010001 |
|---|---|
| Also known as | Pembrolizumab |
| Sponsor | EverNov Medicines (Zhuhai Hengqin) Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EVER4010001 CI brief — competitive landscape report
- EVER4010001 updates RSS · CI watch RSS
- EverNov Medicines (Zhuhai Hengqin) Co., Ltd portfolio CI